SEGMENT REPORTING (Tables)

12 Months Ended

Dec. 31, 2023

Schedule of Segment Reporting Information, by Segment

The following table presents a summary of the revenues and adjusted EBITDA of our three operating segments for the years ended December 31, 2023, 2022, and 2021:


	Year Ended December 31,
(In thousands)	2023		2022		2021
Revenues:
RCM	$	193,929	$	179,870	$	131,242
EHR
Recurring revenue
Acute Care EHR	$	111,276	$	109,340	$	108,440
Post-acute Care EHR	$	14,712	$	15,384	$	16,472
Total recurring EHR revenues	125,988		124,724		124,912
Non-recurring revenue
Acute Care EHR	$	10,657	$	13,138	$	16,939
Post-acute Care EHR	$	1,418	$	1,961	$	1,258
Total non-recurring EHR revenues	12,075		15,099		18,197
Total EHR revenue	138,063		139,823		143,109
Patient engagement	7,443		6,955		6,278
Total revenues	$	339,435	$	326,648	$	280,629

Adjusted EBITDA by Segment:
RCM	24,800		35,219		28,265
EHR	22,900		22,507		26,505
Patient engagement	(124)		(1,827)		(2,093)
Total adjusted EBITDA	$	47,576	$	55,899	$	52,677

Reconciliation Of Net Income From Continuing Operations To Adjusted Income (Loss) From Before Interest, Taxes, Depreciation And Amortization

The following table reconciles net income to adjusted EBITDA:


	Year Ended December 31,
(In thousands)	2023		2022		2021
Net income (loss), as reported	$	(45,789)	$	15,867	$	18,430
Deferred revenue and other acquisition-related adjustments	—		109		747
Depreciation expense	1,946		2,443		2,156
Amortization of software development costs	8,096		3,484		931
Amortization of acquisition-related intangibles	16,426		17,403		13,786
Stock-based compensation	3,271		5,173		5,457
Severance and other non-recurring charges	22,186		4,504		4,892
Interest expense and other, net	11,776		5,267		1,632
Impairment of goodwill	35,913		—		—
Impairment of trademark intangibles	2,342		—		—
Gain on contingent consideration	—		(565)		—
Provision (benefit) for income taxes	(8,591)		2,214		4,646
Total adjusted EBITDA	$	47,576	$	55,899	$	52,677